Contrary to popular belief, labs like Anthropic are allocating a growing percentage of new compute to R&D, not inference. The logic is that the long-term economic return from building AGI is far greater than the immediate revenue from selling tokens, justifying the sacrifice of short-term profits.

Anthropic's core strategy is that possessing the most powerful AI model provides a dual advantage. It not only serves high-end use cases but also acts as an internal tool to accelerate AI research, enabling the company to produce smaller, cheaper models more quickly than competitors.

The business model of selling AI access via tokens is just the start. The truly immense value creation will occur when labs turn their AGI inward to solve humanity's biggest scientific challenges, like longevity, clean energy, and materials science, capturing the resulting value.

Unlike language models trained on existing internet data, Biohub's biological models require data that doesn't exist yet. Their strategy pairs a frontier AI lab with a "frontier biology" effort to invent new imaging and measurement tools, creating proprietary data streams to fuel their models.

Anthropic's core product team was too small to explore frontier AI applications, focusing instead on incremental updates. The Labs division was created specifically to build next-generation products that could showcase the exponential growth of their AI models, ensuring the product roadmap kept pace with the technology curve.

Anthropic's intense focus on AI for coding wasn't just a market strategy. The core belief, held since 2021, was that creating the best coding models would accelerate their internal researchers' work, creating a powerful flywheel that improves their foundational models faster than competitors.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

Anthropic is poised to become a dominant force in life sciences. This is driven by CEO Dario Amodei's passion, the strategic hire of AlphaFold's lead John Jumper, and the launch of a proprietary drug discovery program. This focus mirrors their successful strategy in coding, signaling a move beyond being just a horizontal AI provider.

Frontier model providers like OpenAI and Anthropic are under immense pressure to monetize beyond tokens, forcing them to compete at the application layer. Startups building on their platforms are providing valuable data that will be used to create competitive products, effectively training their own replacement.